Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 2846-2851

  Wire, Mary B ^a   McLean, Heidi B ^a   Pendry, Carolyn ^a   Theodore, Dickens ^a   Park, Jung W ^a,b   Peng, Bin ^a,c  

^a GLAXOSMITHKLINE   (United States)

^b Astellas   (United States)

^c Novartis ^*  (China)

Author keywords

[No Author keywords available]

Indexed keywords

ELTROMBOPAG; LOPINAVIR PLUS RITONAVIR;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CONJUNCTIVAL HYPEREMIA; CROSSOVER PROCEDURE; DECREASED APPETITE; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; DYSGEUSIA; EDEMA; FATIGUE; FEMALE; FLATULENCE; FLUSHING; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH DISCOMFORT; VOMITING;

ADOLESCENT; ADULT; BENZOATES; DRUG INTERACTIONS; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; HYDRAZINES; LOPINAVIR; MALE; MIDDLE AGED; PYRAZOLES; RITONAVIR; YOUNG ADULT;

EID: 84861120207     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05214-11     Document Type: Article

References (29)

1. Abbott Laboratories. 2011. Kaletra (lopinavir/ritonavir) tablets and oral solution product monograph. Abbott Laboratories, North Chicago, IL.
2. Afdhal N, et al. 2011. Final results of ENABLE 1, a phase 3, multicenter study of eltrombopag as an adjunct for antiviral treatment of hepatitis C Virus-related chronic liver disease associated with thrombocytopenia, abstract LB-3. Abstr. 62nd Am. Assoc. Study Liver Dis. Annu. Meet. American Association for the Study of Liver Diseases, Alexandria, VA.
3. Allred AJ, et al. 2011. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers. Br. J. Clin. Pharmacol. 72:321-329.
4. Bouldouyre M-A, et al. 2009. Incidence and risk factors of thrombocytopenia in patients receiving intermittent antiretroviral therapy: a sub-study of the ANRS 106-window trial. J. Acquir. Immune Defic. Syndr 52:531-537.
5. Burger D, Jacobs BS, Colbers EPH, Velthoven-Graafland K, Schouwenberg BJJW. 2011. Effect of fosamprenavir/ritonavir on the pharmacokinetics of single-dose olanzapine in healthy volunteers, abstr P-10. 12th Int. Workshop Clin. Pharmacol. HIV Ther.
6. Bussel JB, et al. 2007. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N. Engl. J. Med. 357:2237-2247.
7. Bussel JB, et al. 2009. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomized, double-blind, placebo-controlled trial. Lancet 373: 641-648.
8. Cheng G, et al. 2011. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomized, phase 3 study. Lancet 377:393-402.
9. Corona G, et al. 2008. Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi 's sarcoma. Clin. Pharmacol. Ther. 83:601-606.
10. Dumond JB, et al. 2010. A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/ inducer tipranavir/ritonavir. Clin. Pharmacol. Ther. 87:735-742.
11. Erickson-Miller CL, et al. 2009. Preclinical activity of eltrombopag (SB-497115), an oral, non-peptide thrombopoietin receptor agonist. Stem Cells 27:424-430.
12. Foisy MM, Yakiwchuk EM, Hughes CA. 2008. Induction effects of ritonavir: implications for drug interactions. Ann. Pharmacother. 42: 1048-1059.
13. GlaxoSmithKline. 2011. Promacta (eltrombopag) tablets product monograph. GlaxoSmithKline, Research Triangle Park, NC.
14. Hsu A, et al. 2003. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 47:350-359.
15. Jenkins J, Williams D, Deng Y, Collins DA, Kitchen VS. 2010. Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 enzymes CYP3A4, CYP1A2, CYP2C9, and CYP2C19 in healthy men: a cocktail analysis. Eur. J. Clin. Pharmacol. 66:67-76.
16. Jenkins JM, et al. 2007. Phase I clinical study of eltrombopag, an oral, non-peptide thrombopoietin receptor agonist. Blood 109:4739-4741.
17. Kellum A, et al. 2010. A randomized, double-blind, placebo-controlled dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors. Curr. Med. Res. Opin. 26:2339-2346.
18. Kirby BJ, et al. 2011. Complex drug interactions of hiv protease inhibitors 2: in vivo induction and in vitro correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir. Drug Metab. Dispos. 39:2329-2337.
19. Kiser JJ, et al. 2008. Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J. Acquir. Immune Syndr. 47:570-578.
20. LaPorte CJL, et al. 2004. Pharmacokinetics of adjusted-dose lopinavirritonavir combined with rifampin in healthy volunteers. Antimicrob. Agents Chemother. 48:1553-1560.
21. Lim ML, et al. 2004. Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J. Acquir. Immune Defic. Syndr. 36:1034-1040.
22. Marks KM, Clarke RMA, Bussel JB, Talal AH, Glesby MJ. 2009. Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 52:595-599.
23. McHutchison JG, et al. 2007. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N. Engl. J. Med. 357: 2227-2236.
24. Passos AM, Treitinger A, Spada C. 2010. An overview of the mechanisms of HIV-related thrombocytopenia. Acta Haematol. 124:13-18.
25. Van der Lee MJ, et al. 2006. Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin. Pharmacol. Ther. 80: 159-168.
26. Waters LI, et al. 2007. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients. Antiviral Ther. 12:825-830.
27. Williams JA, et al. 2004. Drug-drug interactions for UDP-glucuronosyl transferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab. Dispos. 32:1201-1208.
28. Wyen C, et al. 2008. Effect of an antitretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6, and P-glycoprotein in HIV-infected patients. Clin. Pharmacol. Ther. 84: 75-82.
29. Yeh RF, et al. 2006. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J. Acquir. Immune Defic. Syndr. 42: 52-60.